Greenwich LifeSciences Inc
GLSI
Get informed when a big investor buys or sells
+ FollowMarket Cap$278.74M
Close$
$0.46
97.5% downside
Current Fair Value
97.5% downsideOvervalued by 97.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $278.74 Million |
|---|---|
| Enterprise Value | $269.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.43 |
| Beta | 1.46 |
| Outstanding Shares | 14,621,230 |
Return
| Return on Equity | -695.56% |
|---|---|
| Return on Assets | -244.25% |
| Return on Invested Capital | -699.21% |
Valuation & Multiples
| P/E Ratio | -12.33 |
|---|---|
| PEG | 647.97 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 75846.77 |
| Enterprise Value to EBIT | -12.38 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.34
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.66%▼ 0.10% |
|---|---|
| Total Invested | $39.97M▼ 2.83% |
| Investors Holding | 60▼ 3.00% |
ESG Score
No data
About Greenwich LifeSciences Inc
2 employeesGreenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transm...